Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.58 |
| ▸ | CCR5 | P51681 | 4/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974674 | 1.00 | DPP4 (0.58) | DPP4CCR5RORCKDM1ASIGMAR1 | |
| SCHEMBL1975920 | 0.90 | DPP4 (0.58) | DPP4CCR5RORCSIGMAR1DRD2 | |
| SCHEMBL1975922 | 0.90 | DPP4 (0.58) | DPP4CCR5RORCSIGMAR1DRD2 | |
| SCHEMBL1975666 | 0.88 | DPP4 (0.62) | DPP4CCR5RORCSIGMAR1DRD2 | |
| SCHEMBL1975606 | 0.88 | DPP4 (0.62) | DPP4CCR5RORCSIGMAR1DRD2 | |
| SCHEMBL1975608 | 0.88 | DPP4 (0.62) | DPP4CCR5RORCSIGMAR1DRD2 | |
| SCHEMBL2226952 | 0.85 | CCR5 (0.51) | DPP4CCR5RORCKDM1ASIGMAR1 | |
| SCHEMBL1977454 | 0.85 | CCR5 (0.51) | DPP4CCR5RORCKDM1ASIGMAR1 | |
| SCHEMBL2228606 | 0.82 | KDM1A (0.44) | DPP4CCR5RORCKDM1ASIGMAR1 | |
| SCHEMBL1977456 | 0.82 | KDM1A (0.44) | DPP4CCR5RORCKDM1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9226916-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| EP-2513052-B1 | PYRROLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-06-04 | — | — | EP | disclosed |
| US-20130184249-A1 | PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20110144081-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144081-A1 | PYRROLIDINE DERIVATIVES | TACR1, OPRL1, SLC6A3 | DPP4 999/4885CCR5 649/4885RORC 1097/4885 |
| US-20130184249-A1 | PYRROLIDINE DERIVATIVES | TACR1, OPRL1, SLC6A3 | DPP4 999/4885CCR5 649/4885RORC 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.